With the publication of CANTOS (the Canakinumab Anti-inflammatory Thrombosis Outcomes
Study) in 2017, the cardiovascular community received proof of principle that therapeutic …

Over the past 40 years, the most successful pharmacologic approach to cardiovascular
disease prevention has been aggressive lowering of LDL cholesterol. Yet, cardiologists and …

In the rapidly evolving story of inflammation and atherothrombosis, all roads seem to
converge on interleukin (IL)-6, a central signaling cytokine of innate immunity (1). More than …

The initiation of atherosclerosis and its progression to an acute coronary syndrome (ACS)
are intricate processes with many factors, but one central factor is inflammation. Interleukin-6 …

For many patients with established atherosclerotic cardiovascular disease (ASCVD), the 10-
year risk of another acute coronary syndrome is> 30%(1). For others, that risk is …

BACKGROUND: Inflammation contributes to all phases of the atherothrombotic process, and
patients with elevated inflammatory biomarkers such as high-sensitivity C-reactive protein …

The famous German pathologist of the 19th century, Rudolf Virchow of the Charité in Berlin,
was the first to point to the role of inflammation in atherosclerosis, when he …

This editorial refers to 'Residual inflammatory risk associated with interleukin-18 and
interleukin-6 after successful interleukin-1b inhibition with canakinumab: further rationale for …

Circulation. 2018; 138: 150–153. DOI: 10.1161/CIRCULATIONAHA. 118.035107 July 10,
2018 151 low LDL-C levels for further residual risk reduction. Meanwhile, 3 large clinical …

Abstract Interleukin 1β (IL-1β) is a proinflammatory cytokine that has been implicated in a
number of rheumatologic and inflammatory conditions. The production and secretion of IL …